CAAX-box protein, prenylation process and carcinogenesis

American Journal of Translational Research

Volumn 1, Issue 3, 2009, Pages 312-325

  Gao, Juehua ^a   Liao, Jie ^a   Yang, Guang Yu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarkers; CAAX box proteins; Carcinogenesis; Prenylation; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CAAX BOX PROTEIN; CELL PROTEIN; CENTROMERE PROTEIN E; CENTROMERE PROTEIN F; CHAPERONE; CISPLATIN; CYTOTOXIC AGENT; DIMETHYLALLYLTRANSFERASE; ENZYME INHIBITOR; FLUOROURACIL; GERANYLGERANYLTRANSFERASE INHIBITOR; GERANYLGERANYLTRANSFERASE TYPE 1; GLIOTOXIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIN; MEMBRANE PROTEIN; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN HDJ2; PROTEIN HSPXF; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; TRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHEMICALLY INDUCED DISORDER; CHEMOPROPHYLAXIS; COLON CANCER; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG POTENTIATION; DRUG SCREENING; ENZYME INHIBITION; HUMAN; LIVER CANCER; LUNG CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; ONCOGENE H RAS; ONCOGENE N RAS; PROTEIN FUNCTION; PROTEIN PRENYLATION; PROTEIN TARGETING; RADIOSENSITIZATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 77953470577     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Appels NM, Beijnen JH and Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005; 10: 565-578.
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
3. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
4. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL and Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554.
5. Fernandez C, Chetaille B, Tasei AM, Sastre B, Sahel J and Payan-Defais MJ. From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. Gastroenterol Clin Biol 2005; 29: 465-468.
6. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB and Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7: 17-23.
7. Takada S and Koike K. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene 1989; 4: 189-193.
8. Auewarakul CU, Lauhakirti D and Tocharoentanaphol C. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol 2006; 77: 51-56.
9. van Dijk MC, Bernsen MR and Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005; 29: 1145-1151.
10. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF and de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 2003; 88: 2745-2752.
11. Boulalas I, Zaravinos A, Karyotis I, Delakas D and Spandidos DA. Activation of RAS family genes in urothelial carcinoma. J Urol 2009; 181: 2312-2319.
12. Yuan TL and Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
13. Dhomen N and Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007; 17: 31-39.
14. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18 Suppl 2: S19-32.
15. Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, Cox AD, Wilson O, Kirschmeier P and Der CJ. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem 2008; 283: 25150-25163.
16. Preudhomme C, Roumier C, Hildebrand MP, Dallery-Prudhomme E, Lantoine D, Lai JL, Daudignon A, Adenis C, Bauters F, Fenaux P, Kerckaert JP and Galiegue-Zouitina S. Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene 2000; 19: 2023-2032.
17. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R and Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-346.
18. Tang Y, Olufemi L, Wang MT and Nie D. Role of Rho GTPases in breast cancer. Front Biosci 2008; 13: 759-776.
19. Wilson KL, Zastrow MS and Lee KK. Lamins and disease: insights into nuclear infrastructure. Cell 2001; 104: 647-650.
20. Beck LA, Hosick TJ and Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990; 110: 1489-1499.
21. Cohen M, Lee KK, Wilson KL and Gruenbaum Y. Transcriptional repression, apoptosis, human disease and the functional evolution of the nuclear lamina. Trends Biochem Sci 2001; 26: 41-47.
22. Johnson BR, Nitta RT, Frock RL, Mounkes L, Barbie DA, Stewart CL, Harlow E and Kennedy BK. A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc Natl Acad Sci U S A 2004; 101: 9677-9682.
23. Liu B and Zhou Z. Lamin A/C, laminopathies and premature ageing. Histol Histopathol 2008; 23: 747-763.
24. Kammerer S, Arnold N, Gutensohn W, Mewes HW, Kunau WH, Hofler G, Roscher AA and Braun A. Genomic organization and molecular characterization of a gene encoding HsPXF, a human peroxisomal farnesylated protein. Genomics 1997; 45: 200-210.
25. Hussein D and Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 2002; 115: 3403-3414.
26. Matzaris M, O'Malley CJ, Badger A, Speed CJ, Bird PI and Mitchell CA. Distinct membrane and cytosolic forms of inositol polyphosphate 5-phosphatase II. Efficient membrane localization requires two discrete domains. J Biol Chem 1998; 273: 8256-8267.
27. Machiels BM, Ramaekers FC, Kuijpers HJ, Groenewoud JS, Oosterhuis JW and Looijenga LH. Nuclear lamin expression in normal testis and testicular germ cell tumours of adolescents and adults. J Pathol 1997; 182: 197-204.
28. Venables RS, McLean S, Luny D, Moteleb E, Morley S, Quinlan RA, Lane EB and Hutchison CJ. Expression of individual lamins in basal cell carcinomas of the skin. Br J Cancer 2001; 84: 512-519.
29. Broers JL and Ramaekers FC. Differentiation markers for lung-cancer sub-types. A comparative study of their expression in vivo and in vitro. Int J Cancer Suppl 1994; 8: 134-137.
30. de la Guardia C, Casiano CA, Trinidad-Pinedo J and Baez A. CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck 2001; 23: 104-112.
31. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S and Kamata N. Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol 2005; 41: 716-722.
32. O'Brien SL, Fagan A, Fox EJ, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, Higgins DG, Jirstrom K, Landberg G and Gallagher WM. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007; 120: 1434-1443.
33. Adjei AA, Davis JN, Erlichman C, Svingen PA and Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6: 2318-2325.
34. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A and Rosen N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
35. Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ and et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 1994; 91: 9141-9145.
36. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR and et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998; 58: 4947-4956.
37. Ayral-Kaloustian S and Salaski EJ. Protein farnesyltransferase inhibitors. Curr Med Chem 2002; 9: 1003-1032.
38. Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D and Serres M. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 1999; 19: 557-561.
39. Ferrante K, Winograd B and Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43 Suppl: S61-68.
40. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD and Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 2001; 276: 16161-16167.
41. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30: 609-641.
42. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J and Bernhard EJ. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 2001; 61: 2289-2293.
43. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR and Piccart M. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19: 1167-1175.
44. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD and Sebti SM. Antitumor efficacy of a novel class of nonthiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999; 59: 4919-4926.
45. Peterson YK, Kelly P, Weinbaum CA and Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 2006; 281: 12445-12450.
46. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC and Kohl NE. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61: 8758-8768.
47. Singh SV, Mohan RR, Agarwal R, Benson PJ, Hu X, Rudy MA, Xia H, Katoh A, Srivastava SK, Mukhtar H, Gupta V and Zaren HA. Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem Biophys Res Commun 1996; 225: 660-665.
48. Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ and Coombes RC. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol 2004; 21: 21-30.
49. Goldstein JL and Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
50. Duncan RE, El-Sohemy A and Archer MC. Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development. Mol Nutr Food Res 2005; 49: 93-100.
51. Kim KP, Whitehead C, Piazza G and Wargovich MJ. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004; 24: 1805-1811.
52. Blais L, Desgagne A and LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
53. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M and Nakamura H. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-317.
54. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M and Aizawa R. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996; 180: 131-138.
55. Elson CE and Yu SG. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr 1994; 124: 607-614.
56. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192.
57. Rao KN, Kottapally S and Shinozuka H. Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas. Biochim Biophys Acta 1983; 759: 74-80.
58. L Kim JL, L Yan, M Zhang, S Rao and GY Yang. Overexpression of HMG-CoA Reductase, a Potential Therapeutic Target for Pancreatic Adenocarcinoma. Mod Pathol 2007; 20: 284A.
59. Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y and Tarui S. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res 1990; 50: 3270-3273.
60. Caruso MG, Notarnicola M, Santillo M, Cavallini A and Di Leo A. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res 1999; 19: 451-454.
61. Cohen LH and Griffioen M. Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites. Biochem J 1988; 255: 61-67.
62. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992; 339: 1154-1156.
63. Larsson O. HMG-CoA reductase inhibitors: role in normal and malignant cells. Crit Rev Oncol Hematol 1996; 22: 197-212.
64. Horiguchi A, Sumitomo M, Asakuma J, Asano T and Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648-8655.
65. Wachtershauser A, Akoglu B and Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001; 22: 1061-1067.
66. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD and Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40: 167-178.
67. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L and Law RE. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994; 205: 1681-1687.
68. Kawata S, Nagase T, Yamasaki E, Ishiguro H and Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994; 69: 1015-1020.
69. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V and Katoh A. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 1993; 13: 314-324.
70. Wejde J, Blegen H and Larsson O. Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res 1992; 12: 317-324.
71. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ and Kamel-Reid S. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002; 4: 337-346.
72. Maltese WA, Defendini R, Green RA, Sheridan KM and Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 1985; 76: 1748-1754.
73. Hawk MA, Cesen KT, Siglin JC, Stoner GD and Ruch RJ. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett 1996; 109: 217-222.
74. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB and Green JE. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003; 24: 453-459.
75. Sumi S, Beauchamp RD, Townsend CM, Jr., Uchida T, Murakami M, Rajaraman S, Ishizuka J and Thompson JC. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992; 103: 982-989.
76. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J and Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139-1148.
77. Fromigue O, Hamidouche Z and Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008; 283: 30549-30556.
78. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004; 44: 26-35.
79. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L and Rao CV. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006; 66: 4542-4546.
80. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS and Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006; 66: 7370-7377.
81. Philips MR. Compartmentalized signalling of Ras. Biochem Soc Trans 2005; 33: 657-661.
82. Aspenstrom P, Fransson A and Saras J. Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 2004; 377: 327-337.
83. Berzat AC, Buss JE, Chenette EJ, Weinbaum CA, Shutes A, Der CJ, Minden A and Cox AD. Transforming activity of the Rho family GTPase, Wrch-1, a Wnt-regulated Cdc42 homolog, is dependent on a novel carboxyl-terminal palmitoylation motif. J Biol Chem 2005; 280: 33055-33065.
84. Chenette EJ, Abo A and Der CJ. Critical and distinct roles of amino- and carboxyl-terminal sequences in regulation of the biological activity of the Chp atypical Rho GTPase. J Biol Chem 2005; 280: 13784-13792.
85. Canobbio I, Trionfini P, Guidetti GF, Balduini C and Torti M. Targeting of the small GTPase Rap2b, but not Rap1b, to lipid rafts is promoted by palmitoylation at Cys176 and Cys177 and is required for efficient protein activation in human platelets. Cell Signal 2008; 20: 1662-1670.
86. Barrowman J, Hamblet C, George CM and Michaelis S. Analysis of prelamin A biogenesis reveals the nucleus to be a CaaX processing compartment. Mol Biol Cell 2008; 19: 5398-5408.
87. Maske CP, Hollinshead MS, Higbee NC, Bergo MO, Young SG and Vaux DJ. A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J Cell Biol 2003; 162: 1223-1232.
88. Gotte K, Girzalsky W, Linkert M, Baumgart E, Kammerer S, Kunau WH and Erdmann R. Pex19p, a farnesylated protein essential for peroxisome biogenesis. Mol Cell Biol 1998; 18: 616-628.
89. Asano T, Mochizuki Y, Matsumoto K, Takenawa T and Endo T. Pharbin, a novel inositol polyphosphate 5-phosphatase, induces dendritic appearances in fibroblasts. Biochem Biophys Res Commun 1999; 261: 188-195.
90. Hata M and Ohtsuka K. Murine cDNA encoding a novel type I HSP40/DNAJ homolog, mmDjA4(1). Biochim Biophys Acta 2000; 1493: 208-210.